Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Our portfolio includes both biologic and small-molecule immunotherapy product candidates. Our biologic product candidates are based on our proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Our small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase, or IDO, pathway. We believe that our immunotherapeutic technologies have the potential to lead to multiple product candidates, targeting a wide range of oncology indications, that can be used either alone or in combination with other therapies. Our most advanced development-stage programs are based upon our HyperAcute immunotherapy technology. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.12 |
| Quarterly EPS Est: | -0.33 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

